Global COVID-19 Vaccines & Therapeutics 麻豆原创 Research Report 2023

Publication ID:

PB511236417

Publication Date:

November 3, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

IT Services [2]

Hardware (Computing & Electronics) [3]

Computing & Electronics [4]

Description:

COVID-19 Vaccines & Therapeutics are medical products developed to prevent or treat infections caused by the novel coronavirus SARS-CoV-2. Vaccines provide immunity against the virus, while therapeutics aim to alleviate symptoms and reduce the severity of the disease. These products play a critical role in managing the COVID-19 pandemic.
The global COVID-19 Vaccines & Therapeutics market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global COVID-19 Vaccines & Therapeutics market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
Pfizer
Moderna Therapeutics
AstraZeneca
Janssen
Novavax
Gilead Sciences
Eli Lilly and Company
Segment by Type
COVID-19 Vaccines
COVID-19 Therapeutics
Segment by Application
Children
Adult
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The COVID-19 Vaccines & Therapeutics report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. 麻豆原创 Opportunities and Challenges
Chapter 3: Companies鈥� Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies鈥� Outline
Chapter 12: 麻豆原创 Conclusions
Chapter 13: Research Methodology and Data Source

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global COVID-19 Vaccines & Therapeutics 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 COVID-19 Vaccines
1.2.3 COVID-19 Therapeutics
1.3 麻豆原创 by Application
1.3.1 Global COVID-19 Vaccines & Therapeutics 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Children
1.3.3 Adult
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global COVID-19 Vaccines & Therapeutics 麻豆原创 Perspective (2018-2029)
2.2 COVID-19 Vaccines & Therapeutics Growth Trends by Region
2.2.1 Global COVID-19 Vaccines & Therapeutics 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 COVID-19 Vaccines & Therapeutics Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 COVID-19 Vaccines & Therapeutics Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 COVID-19 Vaccines & Therapeutics 麻豆原创 Dynamics
2.3.1 COVID-19 Vaccines & Therapeutics Industry Trends
2.3.2 COVID-19 Vaccines & Therapeutics 麻豆原创 Drivers
2.3.3 COVID-19 Vaccines & Therapeutics 麻豆原创 Challenges
2.3.4 COVID-19 Vaccines & Therapeutics 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top COVID-19 Vaccines & Therapeutics Players by Revenue
3.1.1 Global Top COVID-19 Vaccines & Therapeutics Players by Revenue (2018-2023)
3.1.2 Global COVID-19 Vaccines & Therapeutics Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global COVID-19 Vaccines & Therapeutics 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by COVID-19 Vaccines & Therapeutics Revenue
3.4 Global COVID-19 Vaccines & Therapeutics 麻豆原创 Concentration Ratio
3.4.1 Global COVID-19 Vaccines & Therapeutics 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by COVID-19 Vaccines & Therapeutics Revenue in 2022
3.5 COVID-19 Vaccines & Therapeutics Key Players Head office and Area Served
3.6 Key Players COVID-19 Vaccines & Therapeutics Product Solution and Service
3.7 Date of Enter into COVID-19 Vaccines & Therapeutics 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 COVID-19 Vaccines & Therapeutics Breakdown Data by Type
4.1 Global COVID-19 Vaccines & Therapeutics Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global COVID-19 Vaccines & Therapeutics Forecasted 麻豆原创 Size by Type (2024-2029)
5 COVID-19 Vaccines & Therapeutics Breakdown Data by Application
5.1 Global COVID-19 Vaccines & Therapeutics Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global COVID-19 Vaccines & Therapeutics Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America COVID-19 Vaccines & Therapeutics 麻豆原创 Size (2018-2029)
6.2 North America COVID-19 Vaccines & Therapeutics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America COVID-19 Vaccines & Therapeutics 麻豆原创 Size by Country (2018-2023)
6.4 North America COVID-19 Vaccines & Therapeutics 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe COVID-19 Vaccines & Therapeutics 麻豆原创 Size (2018-2029)
7.2 Europe COVID-19 Vaccines & Therapeutics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe COVID-19 Vaccines & Therapeutics 麻豆原创 Size by Country (2018-2023)
7.4 Europe COVID-19 Vaccines & Therapeutics 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific COVID-19 Vaccines & Therapeutics 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific COVID-19 Vaccines & Therapeutics 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific COVID-19 Vaccines & Therapeutics 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific COVID-19 Vaccines & Therapeutics 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America COVID-19 Vaccines & Therapeutics 麻豆原创 Size (2018-2029)
9.2 Latin America COVID-19 Vaccines & Therapeutics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America COVID-19 Vaccines & Therapeutics 麻豆原创 Size by Country (2018-2023)
9.4 Latin America COVID-19 Vaccines & Therapeutics 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa COVID-19 Vaccines & Therapeutics 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa COVID-19 Vaccines & Therapeutics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa COVID-19 Vaccines & Therapeutics 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa COVID-19 Vaccines & Therapeutics 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer COVID-19 Vaccines & Therapeutics Introduction
11.1.4 Pfizer Revenue in COVID-19 Vaccines & Therapeutics Business (2018-2023)
11.1.5 Pfizer Recent Development
11.2 Moderna Therapeutics
11.2.1 Moderna Therapeutics Company Detail
11.2.2 Moderna Therapeutics Business Overview
11.2.3 Moderna Therapeutics COVID-19 Vaccines & Therapeutics Introduction
11.2.4 Moderna Therapeutics Revenue in COVID-19 Vaccines & Therapeutics Business (2018-2023)
11.2.5 Moderna Therapeutics Recent Development
11.3 AstraZeneca
11.3.1 AstraZeneca Company Detail
11.3.2 AstraZeneca Business Overview
11.3.3 AstraZeneca COVID-19 Vaccines & Therapeutics Introduction
11.3.4 AstraZeneca Revenue in COVID-19 Vaccines & Therapeutics Business (2018-2023)
11.3.5 AstraZeneca Recent Development
11.4 Janssen
11.4.1 Janssen Company Detail
11.4.2 Janssen Business Overview
11.4.3 Janssen COVID-19 Vaccines & Therapeutics Introduction
11.4.4 Janssen Revenue in COVID-19 Vaccines & Therapeutics Business (2018-2023)
11.4.5 Janssen Recent Development
11.5 Novavax
11.5.1 Novavax Company Detail
11.5.2 Novavax Business Overview
11.5.3 Novavax COVID-19 Vaccines & Therapeutics Introduction
11.5.4 Novavax Revenue in COVID-19 Vaccines & Therapeutics Business (2018-2023)
11.5.5 Novavax Recent Development
11.6 Gilead Sciences
11.6.1 Gilead Sciences Company Detail
11.6.2 Gilead Sciences Business Overview
11.6.3 Gilead Sciences COVID-19 Vaccines & Therapeutics Introduction
11.6.4 Gilead Sciences Revenue in COVID-19 Vaccines & Therapeutics Business (2018-2023)
11.6.5 Gilead Sciences Recent Development
11.7 Eli Lilly and Company
11.7.1 Eli Lilly and Company Company Detail
11.7.2 Eli Lilly and Company Business Overview
11.7.3 Eli Lilly and Company COVID-19 Vaccines & Therapeutics Introduction
11.7.4 Eli Lilly and Company Revenue in COVID-19 Vaccines & Therapeutics Business (2018-2023)
11.7.5 Eli Lilly and Company Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Pfizer
Moderna Therapeutics
AstraZeneca
Janssen
Novavax
Gilead Sciences
Eli Lilly and Company

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.